# Journal of Clinical Pharmacy and Therapeutics

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/journal-of-clinical-pharmacy-and-therapeutics/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 0269-4727 |
| ISSNs | 0269-4727,1365-2710 |
| OpenAlex ID | https://openalex.org/S156693432 |
| Publisher | Wiley |

## Journal papers

- [Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy](https://scholariq.org/papers/meta-analysis-of-the-effectiveness-of-smoking-cessation-interventions-in/)
- [ANRIL and atherosclerosis](https://scholariq.org/papers/anril-and-atherosclerosis/)
- [Factors affecting the uptake of new medicines in secondary care a literature review](https://scholariq.org/papers/factors-affecting-the-uptake-of-new-medicines-in-secondary-care-a-literature/)
- [The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians](https://scholariq.org/papers/the-gift-relationship-between-pharmaceutical-companies-and-physicians-an/)
- [Consumers' preference and willingness to pay for pharmacist counselling for non-prescription medicines](https://scholariq.org/papers/consumers-preference-and-willingness-to-pay-for-pharmacist-counselling-for-non/)
- [The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis](https://scholariq.org/papers/the-optimal-single-dose-regimen-of-rasburicase-for-management-of-tumour-lysis/)
- [A network meta‐analysis of efficacy and safety of first‐line and second‐line therapies for the management of metastatic renal cell carcinoma](https://scholariq.org/papers/a-network-meta-analysis-of-efficacy-and-safety-of-first-line-and-second-line/)
- [The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis](https://scholariq.org/papers/the-impact-of-smoking-status-on-the-progression-free-survival-of-non-small-cell/)
- [Pharmacokinetic principles of dose adjustment of<scp>mTOR</scp>inhibitors in solid organ transplanted patients](https://scholariq.org/papers/pharmacokinetic-principles-of-dose-adjustment-of-scp-mtor-scp-inhibitors-in/)
- [Estimation of initial phenobarbital dosing in term neonates with moderate‐to‐severe hypoxic ischaemic encephalopathy following perinatal asphyxia](https://scholariq.org/papers/estimation-of-initial-phenobarbital-dosing-in-term-neonates-with-moderate-to/)
- [Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta‐analysis](https://scholariq.org/papers/hepatotoxicity-with-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors/)
- [Angiotensin‐converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta‐analysis](https://scholariq.org/papers/angiotensin-converting-enzyme-inhibitors-prior-to-scleroderma-renal-crisis-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.